These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 26873719)
1. Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target. Goyal G; Fan T; Silberstein PT Fam Cancer; 2016 Jul; 15(3):359-66. PubMed ID: 26873719 [TBL] [Abstract][Full Text] [Related]
2. Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. Agarwal R; Liebe S; Turski ML; Vidwans SJ; Janku F; Garrido-Laguna I; Munoz J; Schwab R; Rodon J; Kurzrock R; Subbiah V; Discov Med; 2014 Dec; 18(101):331-9. PubMed ID: 25549704 [TBL] [Abstract][Full Text] [Related]
3. Systemic therapy options in BRCA mutation-associated breast cancer. Bayraktar S; Glück S Breast Cancer Res Treat; 2012 Sep; 135(2):355-66. PubMed ID: 22791366 [TBL] [Abstract][Full Text] [Related]
4. Advances in PARP inhibitors for the treatment of breast cancer. Dizdar O; Arslan C; Altundag K Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111 [TBL] [Abstract][Full Text] [Related]
5. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. Turk AA; Wisinski KB Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759 [TBL] [Abstract][Full Text] [Related]
6. Evolution of cancer risk assessment and counseling related to psychological, financial and legal implications. Snyder C Fam Cancer; 2016 Jul; 15(3):493-6. PubMed ID: 26920353 [TBL] [Abstract][Full Text] [Related]
7. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. Cerrato A; Morra F; Celetti A J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198 [TBL] [Abstract][Full Text] [Related]
10. [Hereditary breast and ovarian cancer syndrome: Diagnosis and therapeutic implications]. Koual M; Perkins G; Delanoy N; Crespel C; Medioni J; Nguyen-Xuan HT; Douay-Hauser N; Blons H; Le Frère-Belda MA; Molière D; Achen G; Nos C; Balaya V; Montero R; Laurent-Puig P; Bats AS Ann Pathol; 2020 Apr; 40(2):70-77. PubMed ID: 32046878 [TBL] [Abstract][Full Text] [Related]
11. Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance. Oda K; Tanikawa M; Sone K; Mori-Uchino M; Osuga Y; Fujii T Int J Clin Oncol; 2017 Aug; 22(4):611-618. PubMed ID: 28508305 [TBL] [Abstract][Full Text] [Related]
12. Leveraging DNA repair deficiency in gynecologic oncology. Walsh CS; Hodeib M Curr Opin Obstet Gynecol; 2016 Feb; 28(1):24-31. PubMed ID: 26694829 [TBL] [Abstract][Full Text] [Related]
13. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different? Tan DS; Kaye SB Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149 [TBL] [Abstract][Full Text] [Related]
14. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers. Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626 [TBL] [Abstract][Full Text] [Related]
15. Tissue-Specific Carcinogens as Soil to Seed BRCA1/2-Mutant Hereditary Cancers. Singh AK; Yu X Trends Cancer; 2020 Jul; 6(7):559-568. PubMed ID: 32336659 [TBL] [Abstract][Full Text] [Related]
16. Defective DNA repair in hereditary ovarian cancers: Implications for therapy. Burgess BT; Kolesar JM Am J Health Syst Pharm; 2018 Nov; 75(21):1697-1707. PubMed ID: 30228165 [TBL] [Abstract][Full Text] [Related]
17. [Abnormalities of DNA repair and gynecological cancers]. Auguste A; Leary A Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic exploitation of tumor cell defects in homologous recombination. Powell SN; Kachnic LA Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729 [TBL] [Abstract][Full Text] [Related]
19. The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1). Sorscher S; Ansley K; Delaney SD; Ramkissoon S Breast Cancer Res Treat; 2020 Apr; 180(2):511-514. PubMed ID: 32040686 [TBL] [Abstract][Full Text] [Related]
20. BRCA1/2 testing: therapeutic implications for breast cancer management. Tung NM; Garber JE Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]